Erratum: Clinical trials of human papillomavirus vaccines and beyond (Nature Reviews Clinical Oncology (2013) 10 (400-410) DOI:10.1038/nrclinonc.2013.84);Clinical trials of human papillomavirus vaccines and beyond

Nature Reviews Clinical Oncology

Volumn 10, Issue 7, 2013, Pages 400-410

  Lehtinen, Matti ^a   Dillner, Joakim ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CARCINOMA; CANCER STAGING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT CANCER; GENITAL TRACT INFECTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VAGINA TUMOR; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA TUMOR; VULVAR INTRAEPITHELIAL NEOPLASIA;

EID: 84879798247     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.204     Document Type: Erratum

References (111)

1. International Agency for Research on Cancer. A Review of Human Carcinogens. Part B: Biological agents/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 255-314 (Lyon, France, 2009).
2. Paavonen, J. et al. Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161-2170 (2007).
3. Lehtinen, M. et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 89-99 (2012).
4. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
5. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341, c3493 (2010).
6. Collins, S. I. et al. Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study. Int. J. Cancer 114, 498-500 (2005).
7. Winer, R. L. et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157, 218-226 (2003).
8. Kjaer, S. K. et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol. Biomarkers Prev. 14, 1528-1533 (2005).
9. Dillner, J. et al. Seropositivies to human papillomavirus types 16, 18 and 33 capsids and to Chlamydia trachomastis are markers of sexual behaviour. J. Infect. Dis. 173, 1394-1398 (1996).
10. Koutsky, L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102, 3-8 (1997).
11. Winer, R. L. et al. Condom use and the risk of genital human papillomavirus infection in young women. N. Engl. J. Med. 354, 2645-2654 (2006).
12. Wawer, M. J. et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet 377, 209-218 (2011).
13. Doorbar, J. The papillomavirus life cycle. J. Clin. Virol. 32, S7-S15 (2005).
14. Moscicki, A. B. et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30, F24-F33 (2012).
15. Clifford, G. M., Hoqwell-Jones, R. & Franceschi, S. Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer. Int. J. Cancer 129, 1702-1794 (2011).
16. Schiffman, M., Clifford, G. & Buonaguro, F. M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agents Cancer 4, 8 (2009).
17. Halec, G. et al. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int. J. Cancer 132, 62-71 (2013).
18. Namujju, P. B. et al. Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. Scand. J. Infect. Dis. 42, 522-526 (2010).
19. Stanley, M. HPV-immune response to infection and vaccination. Infect. Agent Cancer 5, 19 (2010).
20. Kjellberg, L. et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J. Gen. Virol. 80, 391-398 (1999).
21. Lin, S. W. et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS ONE 8, e53067 (2013).
22. Palmroth, J. et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand. J. Infect. Dis. 42, 379-384 (2010).
23. Szarewski, A. et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int. J. Cancer 131, 106-116 (2012).
24. Bulkmans, N. W. et al. High-risk HPV type-specific clearance rates in cervical screening. Br. J. Cancer 96, 1419-1424 (2007).
25. Vanska, S., Lehtinen, M. & Auranen, K. Explaining different HPV clearance rate estimates with different proportions of persistent infections [abstract]. 28th International Papillomavirus Conference EP-412 (2012).
26. Anttila, T. et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285, 47-51 (2001).
27. Lehtinen, M. et al. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex. Transm. Infect. 87, 372-376 (2011).
28. Plummer, M. et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14, 805-814 (2003).
29. Kapeu, A. S. et al. Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am. J. Epidemiol. 169, 480-488 (2009).
30. Luostarinen, T. et al. Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study. Int. J. Cancer http://dx.doi.org/10.1002/ijc.28173.
31. Ylä-Outinen, A. et al. in Chlamydial Infections (eds Stamm, W. E. et al.) 323-326 (Cambridge University Press, New York, 1990).
32. Silins, I. et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer 116, 110-115 (2005).
33. Syrjänen, K. et al. Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CIN. Eur. J. Epidemiol. 22, 723-735 (2007).
34. Simen-Kapeu, A. et al. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. Scand. J. Infect. Dis. 40, 745-751 (2008).
35. Szarewski, A. et al. Effect of smoking cessation on cervical lesion size. Lancet 347, 941-943 (1996).
36. Trottier, H. et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 15, 1274-1280 (2006).
37. Lehtinen, M. et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int. J. Cancer 119, 2612-2619 (2006).
38. Kaasila, M. et al. Population dynamics of serologically defined coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. Int. J. Cancer 125, 2166-2172 (2009).
39. Insinga, R. P. et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol. Biomarkers Prev. 19, 1585-1594 (2010).
40. Merikukka, M. et al. Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33. Int. J. Cancer 128, 1114-1119 (2011).
41. Vaccarella, S. et al. Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J. Infect. Dis. 204, 385-390 (2011).
42. Vaccarella, S. et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J. Infect. Dis. 204, 1500-1504 (2011).
43. Trottier, H. et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis. 197, 1436-1447 (2008).
44. Trottier, H. et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 70, 8569-8577 (2010).
45. Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812-1823 (2011).
46. Serre, K. et al. IL-4 directs both CD4 and CD8 T cells to produce Th2 cytokines in vitro, but only CD4 T cells produce these cytokines in response to alum-precipitated protein in vivo. Mol. Immunol. 47, 1914-1922 (2010).
47. Dauner, J. G., Pan, Y., Hildesheim, A., Harro, C. & Pinto, L. A. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 28, 5407-5413 (2010).
48. Giannini, S. L. et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937-5949 (2006).
49. Pedersen, C. et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40, 564-571 (2007).
50. Perez, G. et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int. J. Cancer 122, 1311-1318 (2008).
51. Wheeler, C. M. et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26, 686-696 (2008).
52. Petäjä, T. et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J. Adolesc. Health 44, 33-41 (2009).
53. Vesikari, T. et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr. Infect. Dis. J. 29, 314-318 (2010).
54. Giuliano, A. R. Human papillomavirus vaccination in males. Gynecol. Oncol. 107, S24-S26 (2007).
55. Kapeu, A. Epidemiological Study of Tobacco Use and Human Papillomavirus Thesis, University of Tampere (2009).
56. Villa, L. L. et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95, 1459-1466 (2006).
57. Roteli-Martins, C. M. et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 3, 390-397 (2012).
58. Olsson, S. E. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931-4939 (2007).
59. Roberts, C., Swoyer, R. & Bryan, J. Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay. Hum. Vaccin. Immunother. 4, 431-434 (2012).
60. Joura, E. A. et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26, 6844-6851 (2008).
61. Einstein, M. H. et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 10, 705-719 (2010).
62. Draper, E. et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29, 8285-8290 (2011).
63. Petäjä, T. et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 ASO4-adjuvanted vaccine in preteen/adolescents girls and young women. Int. J. Cancer 129, 2147-2157 (2011).
64. Cuzick, J. et al. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 108, 908-903 (2013).
65. Szarewski, A. et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against HPV types associated with genital warts [abstract]. EUROGIN 2012 Congress SS 12-2 (2012).
66. Giuliano, A. R. et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364, 401-411 (2011).
67. Wilkin, T. et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. Infect. Dis. 202, 1246-1253 (2010).
68. Muñoz, N. et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst. 102, 325-339 (2010).
69. Carreon, J. D. et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int. J. Gynecol. Pathol. 26, 441-446 (2007).
70. Castle, P. E., Schiffman, M., Wheeler, C. M. & Solomon, D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 113, 18-25 (2009).
71. Kjaer, S. K. et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. (Phila.) 2, 868-878 (2009).
72. Rana, M. M. et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up. Int. J. Cancer 132, 2833-2838 (2013).
73. Brotherton, J. M. et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377, 2085-2092 (2011).
74. Lehtinen, M. et al. Chapter 28: Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24 (Suppl. 3), 233-241 (2006).
75. Palefsky, J. M. et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365, 1576-1585 (2011).
76. Kreimer, A. R. et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 12, 862-870 (2011).
77. Larson, H. J., Cooper, L. Z., Eskola, J., Katz, S. L. & Ratzan, S. Addressing the vaccine confidence gap. Lancet 378, 526-535 (2011).
78. Hviid, A., Steffeld, M., Wohlfahrt, J. & Melbye, M. Childhood vaccination and type 1 diabetes. N. Engl. J. Med. 350, 1398-1404 (2004).
79. Pasternak, B. et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 344, e2794 (2012).
80. Wacholder, S. et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 340, c712 (2010).
81. Chao, C. et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J. Intern. Med. 271, 193-203 (2010).
82. Kim, J. J. & Goldie, S. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339, b3884 (2009).
83. Barnabas, R. V. et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential of vaccination: mathematical modelling analyses. PLoS Med. 3, e138 (2006).
84. Regan, D. G., Philp, D. J., Hocking, J. S. & Law, M. G. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex. Health 4, 147-163 (2007).
85. Lehtinen, M., French, K. M., Dillner, J., Paavonen, J. & Garnett, G. Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy 5, 289-294 (2008).
86. Peltola, H. et al. Mumps and rubella eliminated from Finland. JAMA 284, 2643-2647 (2000).
87. Brabin, L. et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 336, 1056-1058 (2008).
88. Lehtinen, M. & Paavonen, J. Impact of human papillomavirus vaccination depends on effective vaccination strategy. Int. J. Cancer 125, 1490-1491 (2009).
89. Malmqvist, E., Natunen, K., Lehtinen, M. & Helgesson, G. Just implemention of human papillomavirus vaccination. J. Med. Ethics 38, 247-249 (2012).
90. Panagiotopoulos, T., Antoniadou, I. & Valassi-Adam, E. Increase in congenital rubella occurrence in Greece: retrospective survey and systematic review. BMJ 319, 1462-1467 (1999).
91. Rouzier, R. & Giordanella, J. P. Coverage and compliance of human papilloma virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J. Adolesc. Health 47, 237-241 (2010).
92. Taylor, R., Hariri, S., Sterberg, M., Dunne, E. F. & Markowitz, L. E. Human papillomavirus vaccine coverage in the United States: National Health and Nutrition Examination Survey. Prev. Med. 52, 398-400 (2011).
93. Mork, J. et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125-1131 (2001).
94. Shiboski, C. H., Schmidt, B. L. & Jordan, R. C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103, 1843-1849 (2005).
95. Näsman, A. et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int. J. Cancer 125, 362-366 (2009).
96. Brewster, D. H. & Bhatti, L. A. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br. J. Cancer 95, 87-90 (2006).
97. Grulich, A. E., Jin, F., Conway, E. L., Stein, A. N. & Hocking, J. Cancers attributable to human papillomavirus infection. Sex. Health 7, 244-252 (2010).
98. Lehtinen, M. & Paavonen, J. Sound efficacy of prophylactic HPV vaccination: basics and implications. Oncoimmunology 1, 995-996 (2012).
99. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1647-1651 (2002).
100. Romanowski, B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum. Vaccin. 7, 161-169 (2011).
101. Palmroth, J. et al. Occurrence of vaccine and non-vaccine HPV types in adolescent Finnish females 4 years post-vaccination. Int. J. Cancer 131, 2832-2838 (2012).
102. Söderlund-Strand, A. & Dilner, J. High-throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol. Biomarkers Prev. 22, 242-250 (2013).
103. Donovan, B. et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect. Dis. 11, 39-44 (2011).
104. Leval, A. et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl Cancer Inst. 105, 469-474 (2013).
105. Baandrup, L. et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex. Transm. Dis. 40, 130-135 (2013).
106. Garnett, G. P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis. 191, S97-S106 (2005).
107. Stanley, M. Prospects for new HPV vaccines. Curr. Opin. Infect. Dis. 1, 70-75 (2010).
108. Nieto, K. et al. Development of AAVLP (HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS ONE 7, e39741 (2012).
109. Herrero, R. et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 1, 408-419 (2011).
110. Wheeler, C. M. et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 100-110 (2012).
111. Brown, D. R. et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926-935 (2009).